K Number
K031630
Device Name
BIFURCATED ALLERGY SKIN TESTING NEEDLE
Date Cleared
2003-08-07

(72 days)

Product Code
Regulation Number
880.5570
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The bifurcated allergy skin testing needle is indicated for in-vivo diagnostic skin testing using the puncture technique.
Device Description
Not Found
More Information

Not Found

Not Found

No
The summary describes a physical medical device (a needle) for skin testing and contains no mention of software, algorithms, image processing, AI, or ML.

No
The device is indicated for in-vivo diagnostic skin testing, which is a diagnostic procedure, not a therapeutic one. Therapeutic devices are used for treating or preventing diseases.

Yes
The "Intended Use / Indications for Use" states that the device is "indicated for in-vivo diagnostic skin testing using the puncture technique." This explicitly indicates a diagnostic purpose.

No

The device is described as a "bifurcated allergy skin testing needle," which is a physical hardware component used for skin testing. There is no mention of software as the primary or sole component of the device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states "in-vivo diagnostic skin testing". In-vivo means "within the living organism". IVD devices are used "in vitro", meaning "outside the living organism", typically on samples of bodily fluids or tissues.
  • Device Description (or lack thereof): While the description is missing, the intended use points to a physical tool used directly on the patient's skin.
  • Anatomical Site: The anatomical site is "Skin", which is a living tissue within the body.

Therefore, the bifurcated allergy skin testing needle, as described, is an in-vivo diagnostic device, not an in-vitro diagnostic device.

N/A

Intended Use / Indications for Use

The bifurcated allergy skin testing needle is indicated for in-vivo diagnostic skin testing using the puncture technique.

Product codes

SCL

Device Description

Bifurcated Allergy Skin Testing Needle

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Skin

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 880.5570 Hypodermic single lumen needle.

(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. Food & Drug Administration."

November 1, 2024

Precision Medical Products, Incorporated Ronald D. Wolfe Manager, Regulatory Affairs 12 Industrial Way Denver, Pennsylvania 17517

Re: K031630

Trade/Device Name: Bifurcated Allergy Skin Testing Needle Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic single lumen needle Regulatory Class: Class II Product Code: SCL

Dear Ronald D. Wolfe:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated August 7, 2003. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code SCL.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact David Wolloscheck, OHT3: Office of GastroRenal, OB-Gyn, General Hospital and Urology Devices, 301-796-1480, David.Wolloscheck(@fda.hhs.gov.

Sincerely,

David Wolloscheck -S

David Wolloscheck, Ph.D. Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices and Human Factors OHT3: Office of GastroRenal, OB-Gyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

1

Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three stripes representing the three levels of government: federal, state, and local. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle.

Public Health Service

AUG - 7 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Ronald D. Wolfe Manager, Regulatory Affairs Precision Medical Products, Incorporated 12 Industrial Way Denver, Pennsylvania 17517

Re: K031630

Trade/Device Name: Bifurcated Allergy Skin Testing Needle Regulatory Class: Unclassified Product Code: LDH Dated: May 21, 2003 Received: May 27, 2003

Dear Mr. Wolfe:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration

2

Page 2 - Mr. Wolfe

and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801). please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Susan Ruanes

Susan Runner, DDS, MA Interim Director Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

3

ミ INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K031430

Bifurcated Allergy Skin Testing Needle Device Name:

Indications for Use:

The bifurcated allergy skin testing needle is indicated for in-vivo diagnostic skin testing using the puncture technique.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Patuxo Cuccento

510(k) Number: K031630

5